3-(benzyloxy)-2-(decyloxy)propan-1-ol | 181173-55-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(benzyloxy)-2-(decyloxy)propan-1-ol
• 英文别名: 2-Decoxy-3-phenylmethoxypropan-1-ol
• CAS: 181173-55-7
• 化学式: C₂₀H₃₄O₃
• 分子量: 322.488
• InChiKey: OREBKASLCWORDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  23
• 可旋转键数：
  15
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(benzyloxy)-2-(decyloxy)propan-1-ol 在 aluminum (III) chloride 、 苯甲醚 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 25.0h， 生成
  参考文献：
  名称：

  直链，支链和拟臂半氟化三亲聚合物的合成，理化性质和自组装。

  摘要：

  合成并表征了同时含有疏水性和亲氟性的直链，支链和米克两亲物，并试图阐明半氟化两亲物结构与水溶液中聚集行为之间的关系。对于线性和分支的两亲物，随着碳氟化合物链段长度的增加，临界聚集浓度（CMC）呈指数下降，核心微粘度呈对数增加；而miktoarm架构在微粘度或CMC方面没有产生明显的趋势。此外，线性和分支的表面活性剂显示出增强的动力学稳定性，在人血清存在下的解离比分支或两臂两亲物更慢。最后，疏水性药物紫杉醇（PTX）的包封研究表明，对于线性和二分支两亲物，其溶解和保留PTX的能力随碳氟化合物部分的存在和碳氟化合物部分尺寸的增加而增加，而对于miktoarm两亲物则未观察到这种趋势。©2014 Wiley Periodicals，Inc. J. Polym。科学，A部分：Polym。化学2014，52，3324-3336

  DOI：

  10.1002/pola.27394
• 作为产物：
  描述：

  methanesulfonic acid decyl ester 在 二异丁基氢化铝 、 potassium hydroxide 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 126.0h， 生成 3-(benzyloxy)-2-(decyloxy)propan-1-ol
  参考文献：
  名称：

  直链，支链和拟臂半氟化三亲聚合物的合成，理化性质和自组装。

  摘要：

  合成并表征了同时含有疏水性和亲氟性的直链，支链和米克两亲物，并试图阐明半氟化两亲物结构与水溶液中聚集行为之间的关系。对于线性和分支的两亲物，随着碳氟化合物链段长度的增加，临界聚集浓度（CMC）呈指数下降，核心微粘度呈对数增加；而miktoarm架构在微粘度或CMC方面没有产生明显的趋势。此外，线性和分支的表面活性剂显示出增强的动力学稳定性，在人血清存在下的解离比分支或两臂两亲物更慢。最后，疏水性药物紫杉醇（PTX）的包封研究表明，对于线性和二分支两亲物，其溶解和保留PTX的能力随碳氟化合物部分的存在和碳氟化合物部分尺寸的增加而增加，而对于miktoarm两亲物则未观察到这种趋势。©2014 Wiley Periodicals，Inc. J. Polym。科学，A部分：Polym。化学2014，52，3324-3336

  DOI：

  10.1002/pola.27394

文献信息

• [EN] FLUOROPOLYMER EMULSIONS WITH PERHALOGENATED STABILIZER FOR THE DELIVERY OF HYDROPHOBIC DRUGS<br/>[FR] ÉMULSIONS DE FLUOROPOLYMÈRES AVEC STABILISATEUR PERHALOGÉNÉ POUR L'ADMINISTRATION DE MÉDICAMENTS HYDROPHOBES
  申请人：WISCONSIN ALUMNI RES FOUND

  公开号：WO2015164756A1

  公开（公告）日：2015-10-29

  The present invention provides therapeutic formulations, including therapeutic nanoemulsions, and related methods for the in vivo delivery of hydrophobic compounds, including an important class of hydrophobic anesthetics. Formulations and methods of the invention include semifluorinated block copolymers and perhalogenated fluorous compounds, such as perfluorooctyl bromide or perfluorodecalin, capable of forming a stable nanoemulsion without the need of conventional lipid components that support bacterial and/or fungal growth (e.g., soybean oil and similar lipids). In certain embodiments, emulsion-based formulations are provided that are capable of formulating, delivering and releasing amounts of hydrophobic drugs effective for a range of clinical applications, including inducing and maintaining anesthesia in patients. In certain embodiments, emulsion-based formulations are provided that are capable of supporting controlled release, for example, over a range of rates useful for clinical applications including rapid and sustained release.

  本发明提供治疗配方，包括治疗纳米乳剂，以及相关的方法，用于体内输送疏水性化合物，包括一类重要的疏水性麻醉剂。该发明的配方和方法包括半氟化块共聚物和全氟化氟化合物，例如全氟辛基溴化物或全氟癸烷，能够形成稳定的纳米乳剂，无需传统的支持细菌和/或真菌生长的脂质成分（例如大豆油和类似脂质）。在某些实施方式中，提供了基于乳剂的配方，能够制备、输送和释放对一系列临床应用有效的疏水药物，包括诱导和维持患者麻醉。在某些实施方式中，提供了基于乳剂的配方，能够支持受控释放，例如在一系列有用于临床应用的速率范围内，包括快速和持续释放。
• [EN] FLUOROPOLYMER EMULSIONS WITH BRANCHED SEMIFLUORINATED BLOCK COPOLYMER OR PHOSPHOLIPID SURFACTANT FOR THE DELIVERY OF HYDROPHOBIC DRUGS<br/>[FR] ÉMULSIONS DE FLUOROPOLYMÈRES COMPORTANT DES COPOLYMÈRES SÉQUENCÉS SEMI-FLUORÉS ET RAMIFIÉS OU UN TENSIOACTIF PHOSPHOLIPIDIQUE POUR L'ADMINISTRATION DE MÉDICAMENTS HYDROPHOBES
  申请人：WISCONSIN ALUMNI RES FOUND

  公开号：WO2015164781A1

  公开（公告）日：2015-10-29

  The present invention provides therapeutic formulations, including therapeutic nanoemulsions, and related methods for the in vivo delivery of hydrophobic compounds, including an important class of hydrophobic anesthetics. Formulations and methods of the invention include semifluorinated block copolymers, and optionally phospholipid surfactants, capable of forming a stable nanoemulsion without the need of conventional lipid components that support bacterial and/or fungal growth(e.g., soybean oil and similar lipids). In certain embodiments, emulsion-based formulations are provided that are capable of formulating, delivering and releasing amounts of hydrophobic drugs effective for a range of clinical applications, including inducing and maintaining anesthesia in patients. In certain embodiments, emulsion-based formulations are provided that are capable of supporting controlled release, for example, over a range of rates useful for clinical applications including rapid and sustained release.

  本发明提供了治疗配方，包括治疗纳米乳液，以及相关方法，用于体内传递疏水化合物，包括一类重要的疏水麻醉剂。本发明的配方和方法包括半氟化块共聚物，以及可选择的磷脂表面活性剂，能够形成稳定的纳米乳液，而无需传统的支持细菌和/或真菌生长的脂质成分（例如大豆油和类似脂质）。在某些实施例中，提供了基于乳液的配方，能够制备、传递和释放对一系列临床应用有效的疏水药物量，包括在患者中诱导和维持麻醉。在某些实施例中，提供了基于乳液的配方，能够支持受控释放，例如，在一系列对于临床应用有用的速率范围内，包括快速和持续释放。
• Fluoropolymer emulsions with branched semifluorinated block copolymer or phospholipid surfactant for the delivery of hydrophobic drugs
  申请人：Wisconsin Alumni Research Foundation

  公开号：US10426727B2

  公开（公告）日：2019-10-01

  The present invention provides therapeutic formulations, including therapeutic nanoemulsions, and related methods for the in vivo delivery of hydrophobic compounds, including an important class of hydrophobic anesthetics. Formulations and methods of the invention include semifluorinated block copolymers, and optionally phospholipid surfactants, capable of forming a stable nanoemulsion without the need of conventional lipid components that support bacterial and/or fungal growth (e.g., soybean oil and similar lipids). In certain embodiments, emulsion-based formulations are provided that are capable of formulating, delivering and releasing amounts of hydrophobic drugs effective for a range of clinical applications, including inducing and maintaining anesthesia in patients. In certain embodiments, emulsion-based formulations are provided that are capable of supporting controlled release, for example, over a range of rates useful for clinical applications including rapid and sustained release.

  本发明提供了用于体内输送疏水性化合物（包括一类重要的疏水性麻醉剂）的治疗制剂（包括治疗用纳米乳剂）和相关方法。本发明的制剂和方法包括半氟化嵌段共聚物，以及可选的磷脂表面活性剂，它们能够形成稳定的纳米乳液，而不需要支持细菌和/或真菌生长的传统脂质成分（如大豆油和类似脂质）。在某些实施方案中，提供的基于乳液的制剂能够配制、输送和释放对一系列临床应用有效的疏水性药物，包括诱导和维持患者的麻醉。在某些实施方案中，所提供的乳液基制剂能够支持控制释放，例如，在对临床应用有用的速率范围内，包括快速和持续释放。
• Fluoropolymer emulsions with perhalogenated stabilizer for the delivery of hydrophobic drugs
  申请人：Wisconsin Alumni Research Foundation

  公开号：US10758483B2

  公开（公告）日：2020-09-01

  The present invention provides therapeutic formulations, including therapeutic nanoemulsions, and related methods for the in vivo delivery of hydrophobic compounds, including an important class of hydrophobic anesthetics. Formulations and methods of the invention include semifluorinated block copolymers and perhalogenated fluorous compounds, such as perfluorooctyl bromide or perfluorodecalin, capable of forming a stable nanoemulsion without the need of conventional lipid components that support bacterial and/or fungal growth (e.g., soybean oil and similar lipids). In certain embodiments, emulsion-based formulations are provided that are capable of formulating, delivering and releasing amounts of hydrophobic drugs effective for a range of clinical applications, including inducing and maintaining anesthesia in patients. In certain embodiments, emulsion-based formulations are provided that are capable of supporting controlled release, for example, over a range of rates useful for clinical applications including rapid and sustained release.

  本发明提供了用于体内输送疏水性化合物（包括一类重要的疏水性麻醉剂）的治疗制剂（包括治疗用纳米乳剂）和相关方法。本发明的制剂和方法包括半氟化嵌段共聚物和全卤化氟化合物，如全氟溴辛烷或全氟萘烷，它们能够形成稳定的纳米乳液，而不需要支持细菌和/或真菌生长的传统脂质成分（如大豆油和类似脂质）。在某些实施方案中，提供的基于乳液的制剂能够配制、输送和释放对一系列临床应用有效的疏水性药物，包括诱导和维持患者的麻醉。在某些实施方案中，所提供的乳液基制剂能够支持控制释放，例如，在对临床应用有用的速率范围内，包括快速和持续释放。
• Bolalipid Membrane Structure Revealed by Solid-State ²H NMR Spectroscopy
  作者：David P. Holland、Andrey V. Struts、Michael F. Brown、David H. Thompson

  DOI：10.1021/ja710190p

  日期：2008.4.1

  Membranes made from three specifically deuterium-labeled ether-linked bolalipids, [1',1',20',20'-H-2(4)[C(20)BAS-PC, [2',2',19',19'-H-2(4)]C(20)BAS-PC, or [10',11'-H-2(2)]C(20)BAS-PC, were analyzed by H-2 NMR spectroscopy. Unlike more common monopolar, ester-linked phospholipids, C(20)BAS-PC exhibits a high degree of orientational order throughout the membrane and the sn-1 chain of the lipid initially penetrates the bilayer at an orientation different from that of the bilayer normal, resulting in inequivalent deuterium atoms at the C1 position. The approximate hydrophobic layer thickness and area per lipid are 18.4 A and 60.4 A(2), respectively, at 25 degrees C, and their respective thermal expansion coefficients are within 20% of the monopolar phospholipid, DLPC.